Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropstine N01 for chemotherapy/immunotherapy-induced thrombocytopenia in solid tumors
ChiCTR2600125939Phase 4Recruiting
- Sponsor
- Weifang People's Hospital
- Start
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of romiplostim in Non-hematologic malignancy and Thrombocytopenia (2 arms), sponsored by Weifang People's Hospital. Primary endpoint: Platelet recovery time. Started Jun 2026; status: recruiting.
02
Drugs
romiplostim
03
Conditions
Non-hematologic malignancyThrombocytopenia
Beyond the preview
Go deeper on ChiCTR2600125939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125939.